BioBlast® - Search
Biogen reaches agreement with Bio-Thera for tocilizumab biosimilar
Biogen announced it has reached an agreement with Bio-Thera for the development, manufacture and commercialisation of BAT1806 (proposed tocilizumab biosimilar). Under the agreement, Biogen will gain exclusive rights to BAT1806 in all countries excluding China.
Fresenius Kabi announces it will launch its biosimilar adalimumab in Australia in Q2 2021
In its Q4 2020 investor presentation, Fresenius Kabi announced it will launch its biosimilar adalimumab in Australia in Q2 2021 and in Brazil in Q3 2021. Additionally, Fresenius Kabi announced it will launch its biosimilar pegfilgrastim in the US and the EU in Q3/4 2021. Fresenius Kabi’s biosimilar tocilizumab candidate is planned for launch in the US and the EU in 2023. An undisclosed autoimmune biosimilar is planned for a 2024 launch, and an oncology biosimilar in 2025.
Gedeon Richter enters asset purchase agreement with Mycenax Biotech
Gedeon Richter announces it has entered an asset purchase agreement with Mycenax Biotech for the purchase of a biosimilar tocilizumab product. Under the agreement, Richter will receive worldwide rights to develop, manufacture and commercialise the product which is expected to reach global markets in 2025.
Bio-Thera Ph III trials of proposed tocilizumab biosimilar commence
Bio-Thera announces commencement of Ph III trials of BAT1806, its proposed tocilizumab biosimilar. Results are expected in the second half of 2020.
Results from Mycenax Ph I PK clinical trials released
Mycenax announces positive results from Ph I PK clinical trials, reporting the product met the primary endpoint in PK comparison.
Product specific reports based on extracts from our BioBlast® database
BioBlast® Editor and Contributing Author
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to recieve our updates via email.